Healthcare Stocks Are Back In Focus
Healthcare stocks remain popular during the latest bout of selling pressure within the broader markets. Despite potential drug-price controls, investors are seeing a number of strong drug pipelines and promising clinical trials. The Frost & Sullivan Healthcare and Life Sciences experts are predicting big disruptions, transformations and innovations in the coming years as the healthcare industry continues to overhaul outmoded business models.
“Our interactive workshop is designed to help managers and CEOs understand key issues affecting the healthcare industry globally,” noted Sandeep Sinha, Vice President & Head, Healthcare and Life Sciences, Frost & Sullivan. “Advances in areas ranging from cancer immunotherapy products to blood testing, as well as the convergence of cutting-edge technology such as artificial intelligence and blockchain will help shape the healthcare industry into a much-anticipated, value-based care paradigm.”
Healthcare stocks remain in focus this week after the stock market posted its worst Black Friday session last week. The Select Sector SPDR Healthcare ETF (XLV) has climbed from lows of $88.98 on Friday to as high as $90.75 Monday as the market pushed higher, led by healthcare stocks.
Premier Health Group, Inc. (PHGRF) (PHGI) provided an update to its previously announced its expansion plans into the Cannabis clinic space by a series of acquisitions, partnerships and/or launching a new Canada-based chain in the first half of 2019. Premier Health has engaged discussions with Licensed Producers under the Access to Cannabis for Medical Purposes Regulation (ACMPR), other licensed medical cannabis companies as well as government officials in order to establish a framework for both patient and physician education.
“Cannabis clinics fit in perfectly with our existing Telemedicine services and comprehensive app plans. The patient will not only be able to see their family doctor with our app, but also connect with their Cannabis clinic healthcare worker, the education nurse and eventually even the pharmacy or LP that is providing the prescription. This team based and encompassing approach will provide the best and most convenient care for our patients” said Dr. Essam Hamza, CEO.
The company has also announced its plans to enter the Pharmacy market via acquisition and/or launching a new Canada based pharmacy in H1–2019 and is actively reviewing a pipeline of additional pharmacy partners which include bricks and mortar locations for acquisition and strategic new retail opportunities for pharmacies.
Premier Health focuses on developing innovative approaches that combine human skill-based expertise with emerging technologies for the healthcare industry. The company entered the primary care clinic and healthcare technology business via the HealthVue transaction, obtaining access to a group of four Greater Vancouver-based fully integrated medical clinics with a 10-year history, 22 health care professionals and over 100,000 active patients.
Senseonics Holdings, Inc (SENS) recently reported revenue for Q3 2018 of $5.2 million, compared to $3.6 million for the second quarter of 2018 and $ 2.1 million for the third quarter of 2017. The company also announced that its Eversense® Continuous Glucose Monitoring (CGM) System has received FDA approval for qualified health care providers to be trained and certified to provide patients with the highly accurate sensor that lasts up to three months. Previously, the sensor insertion and removal procedure could only be performed by trained physicians.
“We are pleased with this FDA approval, we can now include nurse practitioners and physician assistants in the growing list of diabetes care professionals who can be certified to place the Eversense CGM System,” said Tim Goodnow, President and CEO of Senseonics. “We believe that allowing additional health care providers to perform the in-office placement procedure for Eversense CGM will enable broader access to patients for this compelling long-term diabetes management technology.”
Senseonics is a medical technology company focused on the design, development and commercialization of transformational glucose monitoring products. Senseonics’ CGM systems, Eversense® and Eversense® XL, include a small sensor inserted under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.
Tyme Technologies, Inc. (TYME) will be featured as a presenting company at the Piper Jaffray Healthcare Conference held on November 27 -29, 2018 at the Lotte New York Palace in New York, NY. Ben Taylor, President and CEO, will provide an overview of the company’s business during the presentation on Nov. 28 at 10:10am and other members from management will be available to participate in one-on-one meetings with investors.
This news followed the announcement of the presentation of mid-stage clinical data from its lead candidate SM-88 targeting metastatic pancreatic cancer at the 2019 Gastrointestinal Cancers Symposium will be held January 17–19 at the Moscone West Building in San Francisco, Calif.
Tyme is a clinical-stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. The company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.
BiosBioScrip, Inc. (BIOS) announced it will host an Analyst and Investor Day on Thursday, December 6, 2018 in Reston, Virginia. Daniel E. Greenleaf, President and CEO, will provide an update of the company’s strategy and business, followed by a discussion with members of BioScrip’s executive management team beginning at 10:30 am. A live webcast of the event and copies of the materials presented will be accessible via the Company’s investor relations website.
Earlier this month, the company reported quarterly losses of $(0.09) per share missing analyst estimates of $(0.08) by 12.5 percent and reported quarterly sales of $180.962 million which beat the analyst estimates of $171.11 million by 5.76 percent. For FY18, the company anticipates net loss in the range of $0.32 per share to $0.26 per share, and revenue in the range of $710 million to $720 million. Analysts had forecast net loss of $0.35 per share on $697.7 million of revenue.
BioScrip, is the largest independent national provider of infusion and home care management solutions, with approximately 2,100 teammates and nearly 70 service locations across the U.S. BioScrip partners with physicians, hospital systems, payors, pharmaceutical manufacturers and skilled nursing facilities to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting.
This Blog is an affiliate of Midam Ventures LLC. Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. MIDAM was hired for a period from 10/1/2018–4/1/2019 to publicly disseminate information about Premier Health Group Inc. Midam was paid $100,000 (CASH) & “500,000” shares of restricted common shares, they own zero shares that were purchased in the open market. Once the (6) six-month restriction is complete on 4/1/2018, Midam plans to sell the “500,000” shares of Premier Health Group Inc. that they hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Midam may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for full Midam disclaimer.
